Johnson & Johnson has made an unusual $10 million deal with Vanderbilt University, whose researchers will work on development of a potential new schizophrenia treatment, all the way up to creating a compound ready for testing in people.
Johnson & Johnson has made an unusual $10 million deal with Vanderbilt University, whose researchers will work on development of a potential new schizophrenia treatment, all the way up to creating a compound ready for testing in people.
